英昔单抗治疗中至重度溃疡性结肠炎的研究进展

Recent advances on infliximab in the treatment of moderate-to-severe ulcerative colitis

英昔单抗(infliximab)是一种抗肿瘤坏死因子-α(TNF-α)的单克隆抗体。目前infliximab在治疗克罗恩病(CD)方面已取得较好的临床疗效,而它在溃疡性结肠炎(UC)中的治疗效果尚无定论。此文就infliximab治疗中至重度UC的研究进展作一综述。

Infliximab is a monoclonal antibody that targets tumor necrosis factor -alpha（TNF-α） and has been shown to be effective for the management of crohn diease （CD）, But the effective for ulcerative colitis（UC） is still uncertain. This review is about recent advances on infliximab in the treatment of moderate-to-severe UC.